[Immunotherapy with transfer factor in hormone-resistant metastasized carcinoma of the prostate].
Fifty-six patients with metastatic hormone-resistant carcinoma of prostate (stage D3) were submitted to immunotherapy with a monthly intramuscular injection of predominantly specific transfer factor (TF) produced in vitro. Patient follow-up ranging from 1 to 8 years revealed completed remission was achieved in one patient, partial remission in 6, and there was no progression of the metastatic disease in 14 patients. The mean patient survival was 17 months, higher than the survival rates reported elsewhere. No negative side effects ascribable to the treatment regimen were observed. All the foregoing findings, particularly the absence of side effects, provide encouraging data on this treatment modality.
Corrado
F
F
Pizza
G
G
de Vinci
C
C
Corrado
G
G
D001859:Bone Neoplasms / Q000188:drug therapy* / Q000556:secondary; D002277:Carcinoma / Q000188:drug therapy* / Q000556:secondary; D004341:Drug Evaluation; D006801:Humans; D007167:Immunotherapy; D008297:Male; D010384:Pelvic Bones; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D013125:Spinal Neoplasms / Q000188:drug therapy / Q000556:secondary; D014165:Transfer Factor / Q000627:therapeutic use*
D014165:Transfer Factor
Immunoterapia con factor de trasferencia en el carcinoma de próstata metastatizado resistente a las hormonas.